Mavorixafor FDA approval date

The FDA approved Mavorixafor (AMD11070) on 26 Apr 2024.

FDA approval date
26 Apr 2024

Drug identity checked against registry records

Also recorded as AMD11070; X4P-001

Included trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2024-04-26DayMavorixaforFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA218709", "applicant_as_listed_by_fda": "X4 PHARMS", "brand_names": ["XOLREMDI"], "active_ingredients": ["MAVORIXAFOR"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20240426", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026